Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Di Carlo, Isidoro ^a   Mannino, Maurizio ^a   Toro, Adriana ^a   Ardiri, Annalisa ^a   Galia, Antonio ^b   Cappello, Giovanni ^a   Bertino, Gaetano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

Author keywords

Alpha fetoprotein; Hcc; Hcc without cirrhosis; Hepatectomy

Indexed keywords

ALLOPURINOL; ALPHA FETOPROTEIN; FOLINIC ACID; PYRIDOXINE;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MALE; NONHODGKIN LYMPHOMA; POSTOPERATIVE PERIOD; TUMOR VOLUME;

AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; POSTOPERATIVE COMPLICATIONS; REVIEW LITERATURE AS TOPIC; VIRUSES;

EID: 84860506934     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-79     Document Type: Article

References (38)

1. Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Clinical evaluation of serum alpha-fetoprotein and circulating immune complexes as tumour markers of hepatocellular carcinoma. Br J Cancer 1995, 72:442-446. 10.1038/bjc.1995.352, 2033981, 7543774.
2. Lang H, Sotiropoulos GC, Dömland M, Frühauf NR, Paul A, Hüsing J, Malagò M, Broelsch CE. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005, 92:198-202. 10.1002/bjs.4763, 15609381.
3. Lubrano J, Huet E, Tsilividis B, François A, Goria O, Riachi G, Scottè M. Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse. World J Surg 2008, 32:104-109. 10.1007/s00268-007-9291-0, 18026787.
4. Yokoi Y, Suzuki S, Baba SK, Inaba K, Konno H, Nakamura S. Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol 2005, 40:274-282. 10.1007/s00535-004-1536-1, 15830287.
5. Hao K, Luk JM, Lee NP, Mao M, Zhang C, Ferguson MD, Lamb J, Dai H, Ng IO, Sham PC, Poon RT. Predicting prognosis in hepatocellular carcinoma after curative surgery with common clinicopathologic parameters. BMC Cancer 2009, 9:389. 10.1186/1471-2407-9-389, 2785835, 19886989.
6. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271-285. 10.1055/s-2007-1007117, 10518307.
7. Kim JH, Choi MS, Lee H, Kim do Y, Lee JH, Koh KC, Yoo BC, Paik SW, Rhee JC. Clinical features and prognosis of hepatocellular carcinoma in young patients from a hepatitis B-endemic area. J Gastroenterol Hepatol 2006, 21:588-594. 10.1111/j.1440-1746.2005.04127.x, 16638104.
8. Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, Tso WK, Fan ST, Poon RT. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008, 207:20-29. 10.1016/j.jamcollsurg.2008.01.020, 18589357.
9. Corey KE, Pratts DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol 2009, 2:45-57. 10.1177/1756283X08100328, 3002509, 21180533.
10. Sherman M. Current status of alpha-fetoprotein testing. Gastroenterol Hepatol (NY) 2011, 7:113-114.
11. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas Villavicencio A, Flores-Estrada D, Hernàndez-Pedro N. The progressive elevation of alpha-fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007, 7:28. 10.1186/1471-2407-7-28, 1803796, 17288606.
12. Gervain J. Symptoms of hepatocellular carcinoma. Laboratory tests used for its diagnosis and screening. Orv Hetil 2010, 151:1415-1417. 10.1556/OH.2010.28945, 20719715.
13. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreas Dis Int 2008, 7:237-757.
14. Shirabe K, Takenaka K, Gion T, Shimada M, Fujiwara Y, Sugimachi K. Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997, 64:143-146. 10.1002/(SICI)1096-9098(199702)64:2<143::AID-JSO10>3.0.CO;2-7, 9047252.
15. Zhou YM, Yang JM, Li B, Yin ZF, Xu F, Wang B, Xu W, Kan T. Risk factors for early recurrence of small hepatocellular carcinoma after curative resection. Hepatobiliary Pancreas Dis Int 2010, 9:33-37.
16. Eleftheriou N, Heathcote J, Thomas HC, Sherlock S. Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma. J Clin Pathol 1977, 30:704-708. 10.1136/jcp.30.8.704, 476528, 74380.
17. Van der Veek PP, de Vos Tot Nederveen Cappel WH, Langers AM, van Hoek B. Two patients with extremely elevated tumor markers: where is the malignancy?. Gastroenterol Res Pract 2011, 123743.
18. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol 2006, 101:524-532. 10.1111/j.1572-0241.2006.00443.x, 16542289.
19. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreas Dis Int 2007, 6:241-247.
20. Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both?. Future Oncol 2009, 5:889-899. 10.2217/fon.09.64, 19663737.
21. Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence?. World J Gatroenterol 2010, 16:3049-3055.
22. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20:65-71. 10.1016/S0168-8278(05)80468-4, 7515408.
23. Chang CH, Chau GY, Lui WY, Tsay S, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg 2004, 139:320-325. 10.1001/archsurg.139.3.320, 15006892.
24. Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Chiu JH, Wu CW, P'eng FK. Prognostic significance of surgical margin in hepatocellular carcinoma resection: an analysis of 165 Childs' A patients. J Surg Oncol 1997, 66:122-126. 10.1002/(SICI)1096-9098(199710)66:2<122::AID-JSO9>3.0.CO;2-F, 9354168.
25. Takano S, Oishi H, Kono S, Kawakami S, Nakamura M, Kubota N, Iwai S. Retrospective analysis of type of hepatic resection for hepatocellular carcinoma. Br J Surg 2000, 87:65-70.
26. Alkofer B, Lepennec V, Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011, 148:3-11. 10.1016/j.jviscsurg.2010.12.012, 21306970.
27. Toonen F, Smilde T. A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma. Neth J Med 2010, 68:33-34.
28. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K, Kataja V. Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:147-154.
29. Kanda T, Yoshida H, Mamada Y, Taniai N, Kawano Y, Mizuguchi Y, Shimizu T, Takahashi T, Ueda J, Kato S, Akimaru K, Tajiri T, Fukuda Y. Resection of liver metastases from an alpha-fetoprotein-producing gastric cancer. J Nihon Med Sch 2005, 72:66-70. 10.1272/jnms.72.66, 15834210.
30. Liu CZ, Hu SY, Wang L, Zhi XT, Jin B, Zhu M, Wachtel MS, Frezza EE. Hepatoid carcinoma of the pancreas: a case report. Chin Med J (Engl) 2007, 120:1850-1852.
31. Kitada M, Ozawa K, Sato K, Matsuda Y, Hayashi S, Tokusashi Y, Miyokawa N, Sasajima T. Alpha-fetoprotein-producing primary lung carcinoma: a case report. World J Surg Oncol 2011, 9:47. 10.1186/1477-7819-9-47, 3103442, 21554678.
32. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003, 68:1075-1082.
33. Babali A, Cakal E, Purnak T, Biyikoĝlu I, Cakal B, Yüksel O, Köklü S. Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int 2009, Nov 5.
34. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010, 16:1436-1441. 10.3748/wjg.v16.i12.1436, 2846247, 20333782.
35. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocyte. Digestion 2011, 83:124-133. 10.1159/000318741, 21042023.
36. Chagas AL, Kikuchi LO, Oliveira JP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?. Braz J Med Biol Res 2009, 42:958-962. 10.1590/S0100-879X2009005000019, 19787150.
37. Houwert AC, Giltay JC, Lentjes EG, Lock MT. Hereditary persistence of alpha-fetoprotein (HPAFP): review of the literature. Neth J Med 2010, 68:354-358.
38. No authors listed Program of the annual meeting of the American Gastroenterology Association for the Study of Liver Diseases, and the Gastroenterology Study Group. Abstracts of Papers. Gastroenterology 1979, 76:1089-1316. No authors listed.